Cosmos Health Inc. expects incremental annual revenue of more than $6 million in the United States within 12 to 18 months following the launch of its Oliv18 nutraceutical product.
The New York-based company projects gross profit of approximately $4.3 million on the projected sales, representing an estimated gross margin of around 72%. Oliv18 is an organic olive polyphenol formulation certified by the U.S. Department of Agriculture and the European Union, produced through a solvent-free process.
The product targets cardiovascular health supplements and antioxidant segments, expanding Cosmos Health’s 18 Series line into two established consumer wellness categories. The company plans a gradual rollout, beginning with direct-to-consumer e-commerce before expanding into selected retail channels.
Cosmos Health, listed on the NASDAQ under the ticker COSM, operates subsidiaries including Cana Laboratories S.A., a manufacturing facility in Thessaloniki, Greece, licensed under European Good Manufacturing Practices and certified by the European Medicines Agency. The company also maintains offices and distribution centers in Athens, Greece, and Harlow, United Kingdom.
Chief Executive Officer Greg Siokas said Oliv18 broadens the company’s presence in the science-backed consumer wellness market, where demand is shifting toward clinically supported products.
